ANGARAI Competitors

Direct Computer Resources, Inc. is the owner and developer of DataVantage software, leading solutions that help organizations solve complex data management, security, and governance challenges. For 40+ years, DataVantage software has supported hundreds of Fortune 500 and Global 1000 organizations with proven technology that now helps businesses navigate the complexities of AI, cloud, and digital transformation. DataVantage software masks and manages mainframe and distributed data to protect PII and other sensitive information to help meet corporate policies and government regulations, such as GDPR, CPRR, DORA, HIPAA, PCI DSS, and more. DataVantage products include: * DataVantage Data Masking Express: Affordable mainframe data masking that works alongside already-installed data management software. * DataVantage for Db2 for z/OS: Data masking and data management for Db2 for z/OS databases. * DataVantage for IMS: Data masking and data management for IMS databases. * DataVantage Global: Enterprise data masking and data management for distributed systems. * DataVantage Adviser: Works with relational data on-prem or in the cloud, NTT Data, and Rocket COBOL (formerly Micro Focus COBOL) files.

With corporate offices in Lafayette, LA, USA, Apex Innovations designs, manufactures and provides unique tools, software, competencies, resources and educational web-based programs for individuals, universities, organizations and corporations around the world. Follow us on Twitter - @ApexInnovations https://twitter.com/ApexInnovations Like Us on Facebook - https://www.facebook.com/Apex.online.continuing.education

With unrivaled expertise in immunology, 5 operating sites in North America and Europe, and a translational offer of services covering the needs of the pharmaceutical industry from the lead selection to the late clinical stage, Nexelis, a Q² Solutions Company, is a leading provider of assay development and advanced laboratory testing services in the infectious, metabolic and oncologic fields. Our versatile team of scientists, working with state of the art technology platforms, were instrumental in the development, qualification, validation, and large-scale sample testing of assays that supported the FDA filing of almost 350 new molecular entities, including blockbuster vaccines and biologics, anti-viral drugs, immunotherapy, gene and cell therapy products.